Please provide your email address to receive an email when new articles are posted on . Women with type 1 diabetes who used insulin degludec during pregnancy had similar HbA1c and glucose profile as ...

March 11, 2011 — Insulin degludec (Novo Nordisk), a novel, ultra-long-acting basal formulation, provides comparable glycemic control to insulin glargine without additional adverse events and may ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky for those with type 1 diabetes, the phase III QWINT-2 and -5 trials showed.

A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its potential to reduce ...

Once-weekly efsitora noninferior to once-daily degludec for decrease in mean glycated hemoglobin level. (HealthDay News) — Once-weekly efsitora is noninferior to once-daily degludec for reducing ...

Results showed treatment with insulin efsitora was noninferior to insulin degludac based on reduction in HbA1c at 52 weeks. Once-weekly insulin efsitora was found to be as effective as daily basal ...

Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 1 diabetes using insulin glargine had ...

The only peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software. A new study in the peer-reviewed journal ...

COPENHAGEN (Reuters) - Studies showed Novo Nordisk's insulin degludec lowered blood sugar levels with significantly reduced rates of hypoglycaemia when compared with rival Sanofi's Lantus, the Danish ...

Add Yahoo as a preferred source to see more of our stories on Google. In people with type 1 diabetes, insulin must be taken every day as their pancreas cannot produce the hormone itself. However a new ...

Insulin efsitora is an investigational basal insulin designed for once-weekly subcutaneous administration. Once-weekly insulin efsitora alfa was found to be as effective as daily basal insulin in ...